Navigating through the Controversies and Emerging Paradigms in Early Detection of Prostate Cancer: Bridging the Gap...

Area of Science:

• Urology
• Oncology
• Public Health

Background:

• Prostate cancer screening has evolved over 30 years, driven by major trials like ERSPC and PLCO.
• Initial debates arose from conflicting trial results and high overdiagnosis rates (up to 50%).
• Recent alignment in trial data confirms PSA screening reduces prostate cancer mortality.

Purpose of the Study:

• To review 30 years of prostate cancer screening evidence.
• To highlight the shift towards individualized, risk-based screening algorithms.
• To introduce the PRAISE-U project for enhanced early detection in the EU.

Main Methods:

• Review of historical data from major prostate cancer screening trials (ERSPC, PLCO).
• Analysis of the evolution of diagnostic algorithms and screening protocols.
• Examination of recent European Commission recommendations for early detection programs.

Main Results:

• PSA screening effectively reduces prostate cancer-specific mortality.
• Significant challenges include high rates of overdiagnosis and associated harms.
• Improved diagnostic tools and risk-based algorithms are emerging.

Conclusions:

• Balancing screening benefits and harms remains a critical challenge.
• Individualized, risk-based screening offers a promising approach to optimize early detection.
• The PRAISE-U project aims to implement customized screening programs for better prostate cancer outcomes.